Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; Marzeptacog alfa (activated) Study Group Investigators. Gruppo RA, et al. Among authors: nemes l. J Thromb Haemost. 2018 Oct;16(10):1984-1993. doi: 10.1111/jth.14247. Epub 2018 Aug 27. J Thromb Haemost. 2018. PMID: 30151972 Free article. Clinical Trial.
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J; Pathfinder™2 Investigators. Giangrande P, et al. Among authors: nemes l. Thromb Haemost. 2017 Jan 26;117(2):252-261. doi: 10.1160/TH16-06-0444. Epub 2016 Dec 1. Thromb Haemost. 2017. PMID: 27904904 Clinical Trial.
Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K. Tosetto A, et al. Among authors: nemes l. Haemophilia. 2020 May;26(3):450-458. doi: 10.1111/hae.13980. Epub 2020 Apr 15. Haemophilia. 2020. PMID: 32293786 Free PMC article. Clinical Trial.
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S. Recht M, et al. Among authors: nemes l. Haemophilia. 2009 Jul;15(4):869-80. doi: 10.1111/j.1365-2516.2009.02027.x. Epub 2009 Apr 9. Haemophilia. 2009. PMID: 19473411
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial.
de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Šalek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. de Paula EV, et al. Among authors: nemes l. J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x. J Thromb Haemost. 2012. PMID: 22470921 Free article. Clinical Trial.
Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R, Nemes L, Jimenez-Yuste V, Rusen L, Cid AR, Charnigo RJ, Baumann JA, Smith L, Korth-Bradley JM, Rendo P. Parra Lopez R, et al. Among authors: nemes l. Thromb Haemost. 2015 Oct;114(4):676-84. doi: 10.1160/TH14-09-0760. Epub 2015 Aug 13. Thromb Haemost. 2015. PMID: 26293201 Clinical Trial.
103 results